Literature DB >> 23541809

A model to estimate the risk of breast cancer-related lymphedema: combinations of treatment-related factors of the number of dissected axillary nodes, adjuvant chemotherapy, and radiation therapy.

Myungsoo Kim1, Seok Won Kim, Sung Uk Lee, Nam Kwon Lee, So-Youn Jung, Tae Hyun Kim, Eun Sook Lee, Han-Sung Kang, Kyung Hwan Shin.   

Abstract

PURPOSE: The development of breast cancer-related lymphedema (LE) is closely related to the number of dissected axillary lymph nodes (N-ALNs), chemotherapy, and radiation therapy. In this study, we attempted to estimate the risk of LE based on combinations of these treatment-related factors. METHODS AND MATERIALS: A total of 772 patients with breast cancer, who underwent primary surgery with axillary lymph node dissection from 2004 to 2009, were retrospectively analyzed. Adjuvant chemotherapy (ACT) was performed in 677 patients (88%). Among patients who received radiation therapy (n=675), 274 (35%) received supraclavicular radiation therapy (SCRT).
RESULTS: At a median follow-up of 5.1 years (range, 3.0-8.3 years), 127 patients had developed LE. The overall 5-year cumulative incidence of LE was 17%. Among the 127 affected patients, LE occurred within 2 years after surgery in 97 (76%) and within 3 years in 115 (91%) patients. Multivariate analysis showed that N-ALN (hazard ratio [HR], 2.81; P<.001), ACT (HR, 4.14; P=.048), and SCRT (HR, 3.24; P<.001) were independent risk factors for LE. The total number of risk factors correlated well with the incidence of LE. Patients with no risk or 1 risk factor showed a significantly lower 5-year probability of LE (3%) than patients with 2 (19%) or 3 risk factors (38%) (P<.001).
CONCLUSIONS: The risk factors associated with LE were N-ALN, ACT, and SCRT. A simple model using combinations of these factors may help clinicians predict the risk of LE.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23541809     DOI: 10.1016/j.ijrobp.2013.02.018

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  18 in total

1.  Timing of Lymphedema After Treatment for Breast Cancer: When Are Patients Most At Risk?

Authors:  Susan G R McDuff; Amir I Mina; Cheryl L Brunelle; Laura Salama; Laura E G Warren; Mohamed Abouegylah; Meyha Swaroop; Melissa N Skolny; Maria Asdourian; Tessa Gillespie; Kayla Daniell; Hoda E Sayegh; George E Naoum; Hui Zheng; Alphonse G Taghian
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-08-28       Impact factor: 7.038

Review 2.  Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments.

Authors:  Tessa C Gillespie; Hoda E Sayegh; Cheryl L Brunelle; Kayla M Daniell; Alphonse G Taghian
Journal:  Gland Surg       Date:  2018-08

3.  Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection.

Authors:  Jane M Armer; Karla V Ballman; Linda McCall; Pamela L Ostby; Eris Zagar; Henry M Kuerer; Kelly K Hunt; Judy C Boughey
Journal:  JAMA Surg       Date:  2019-09-01       Impact factor: 14.766

4.  Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) for Prevention of Breast Cancer-Related Lymphedema-a Preliminary Report.

Authors:  Juhi Agrawal; Sandeep Mehta; Ashish Goel; Pankaj Kumar Pande; Kapil Kumar
Journal:  Indian J Surg Oncol       Date:  2018-02-17

5.  Breast cancer-related lymphedema after axillary lymph node dissection: does early postoperative prediction model work?

Authors:  Atilla Soran; Ebru Menekse; Mark Girgis; Lori DeGore; Ronald Johnson
Journal:  Support Care Cancer       Date:  2015-09-09       Impact factor: 3.603

6.  Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort.

Authors:  Meyha N Swaroop; Chantal M Ferguson; Nora K Horick; Melissa N Skolny; Cynthia L Miller; Lauren S Jammallo; Cheryl L Brunelle; Jean A O'Toole; Steven J Isakoff; Michelle C Specht; Alphonse G Taghian
Journal:  Breast Cancer Res Treat       Date:  2015-05-05       Impact factor: 4.872

7.  Breast Cancer-Related Lymphedema after Neoadjuvant Chemotherapy.

Authors:  Myungsoo Kim; In Hae Park; Keun Seok Lee; Jungsil Ro; So-Youn Jung; Seeyoun Lee; Han-Sung Kang; Eun Sook Lee; Tae Hyun Kim; Kwan Ho Cho; Kyung Hwan Shin
Journal:  Cancer Res Treat       Date:  2014-11-17       Impact factor: 4.679

8.  Role of physiotherapy and patient education in lymphedema control following breast cancer surgery.

Authors:  Shiang-Ru Lu; Rong-Bin Hong; Willy Chou; Pei-Chi Hsiao
Journal:  Ther Clin Risk Manag       Date:  2015-02-25       Impact factor: 2.423

Review 9.  Lymphoedema After Breast Cancer Treatment is Associated With Higher Body Mass Index: A Systematic Review and Meta-Analysis.

Authors:  Astère Manirakiza; Laurent Irakoze; Lin Shui; Sébastien Manirakiza; Louis Ngendahayo
Journal:  East Afr Health Res J       Date:  2019-11-29

10.  Use of a prospective surveillance model to prevent breast cancer treatment-related lymphedema: a single-center experience.

Authors:  Eun Joo Yang; Soyeon Ahn; Eun-Kyu Kim; Eunyoung Kang; Youngmi Park; Jae-Young Lim; Sung-Won Kim
Journal:  Breast Cancer Res Treat       Date:  2016-09-24       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.